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Introduction 
The consumption of fish oil has been associated with reduced cardiovascular risk in 
Greenland Eskimos, who traditionally follow a pescatarian diet. The regular intake of 
n-3 (also called omega-3) fatty acids, which are present in fish oil, has been 
suggested as being of potential benefit in the primary and secondary prevention of 
coronary heart disease, but meta-analysis of trials of n-3 fatty acids have 
demonstrated no significant reduction in major cardiovascular events. Icosapent 
ethyl is a fish oil derivative which has been demonstrated to reduce triglyceride 
levels without increasing low density lipid (LDL) cholesterol.  
Pharmacology 
Isocapent ethyl is a semi-synthetic, long-chain fatty acid ethyl ester condensed from 
the carboxy group of icosapentaenoic acid and an ethanol hydroxyl group. Following 
administration, isocapent ethyl is de-esterified and converted into active 
eicosapentaenoic acid (EPA) which is absorbed in the small bowel. Peak plasma 
concentration is achieved approximately five hours following oral ingestion. It is 
almost completely incorporated into phospholipids, triglycerides and cholesteryl 
esters, with less than one percent remaining in circulating plasma. It is hepatically 
metabolised into acetyl coenzyme A by beta-oxidation with a biological half-life of 89 
hours and plasma clearance rate of 684 ml/hr.  
EPA is a naturally existing long-chain fatty acid found in oily fish and seafood, 
and there is no evidence of toxicity from high dose regimens from existing literature. 
EPA is hypothesised to reduce triglyceride level through the reduction of hepatic 
very-low-density lipoprotein (VLDL) triglyceride synthesis/secretion and through 
enhanced clearance of triglycerides from VLDLs in the circulation. The mechanism of 
action is uncertain but is believed to involve acyl-CoA:1,2-diacylglycerol 
acyltransferase inhibition, decreased hepatic lipogenesis or increased beta-oxidation 
and plasma lipoprotein lipase activity (Figure 1).  
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Trials of safety and efficacy  
The MARINE trial compared icosapent ethyl 2g or 4g/day versus placebo in 229 
patients with elevated triglyceride levels with or without background statin therapy 
(1). Other triglyceride-lowering therapies such as fibrates, and fish oils containing 
both eicosapentaenoic acid and docosahexaenoic acid, can substantially increase 
LDL cholesterol levels when administered to patients with very high TG levels. In 
MARINE icosapent ethyl significantly decreased triglyceride levels  at 12 weeks with 
no change in the placebo-corrected LDL cholesterol levels. The most common 
adverse event was gastrointestinal upset. 
The ANCHOR study compared icosapent ethyl 2g/day or 4g/day versus 
placebo in 702 statin-treated patients who were at high risk of coronary disease with 
residual elevation of triglycerides despite controlled LDL cholesterol levels (2). A 12 
weeks weeks it demonstrated a decrease in placebo-adjusted triglyceride levels from 
baseline by 10% and 21% in the 2g/day and 4g/day arms respectively. LDL 
cholesterol was reduced with icosapent ethyl, and reductions in c-reactive protein as 
a marker of inflammation were also noted. Both dose regimens were well tolerated, 
and there was an increase in arthralgia with icosapent ethyl.  
The Reduction of Cardiovascular Events with Icosapent Ethyl – Intervention 
Trial (REDUCE-IT), studied 8,179 patients who were on statin therapy and had 
raised triglycerides. Subjects were randomised to 2 g of icosapent ethyl twice daily or 
a mineral oil containing placebo and followed for a median of 4.9 years (3). Two 
thirds of the subjects were enrolled on the basis of secondary prevention with 
established cardiovascular disease, and one third on the basis of primary prevention 
with diabetes plus another risk factor. The primary endpoint was a composite of 
cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary 
revascularisation, unstable angina, and subjects were followed for a median of 4.9 
years. The event rate was high at 22% in the placebo group and 17% in the 
treatment group, a statistically significant 25% relative risk reduction. A key 
secondary endpoint of MACE (cardiovascular death, nonfatal myocardial infarction, 
and nonfatal stroke) was also significantly reduced.   
The most commonly reported side-effects were gastrointestinal upset, 
headache, arthralgia and rash. Safety and adverse events reporting in REDUCE-IT 
showed no significant difference in overall rates of adverse events between 
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treatment and placebo arms. A significantly higher incidence of hospitalisation for 
atrial fibrillation or flutter, constipation and peripheral oedema (6.5 vs. 5.0% P=0.002) 
was observed in the intervention group.  
Specific evidence for use in diabetes  
The typical dyslipidaemia seen in people with type 2 diabetes includes raised 
triglycerides so it is not surprising that there were many subjects with diabetes in 
these safety and efficacy trials. 29% of subjects in MARINE and 73% of subjects in 
ANCHOR had diabetes. 58% of subjects in REMOVE-IT had diabetes at baseline 
and the results were similar for subjects with and without diabetes with a 23% 
reduction in the primary endpoint in the diabetes subgroup and a 27% reduction in 
those without diabetes.  
Discussion 
REDUCE-IT demonstrated further reductions in cardiovascular events when 
icosapent ethyl was added to patients who are on statins and have raised triglyceride 
concentrations. The results are similar to the larger open-label Japan EPA Lipid 
Intervention Study (JELIS) which compared a lower dose of EPA pro-drug (1.8g 
daily) in addition to background statin therapy in 18,645 subjects with placebo and 
demonstrated a 19% lower risk of major adverse cardiovascular events (4).  
The reduction in the primary end-point in REDUCE-IT cannot be explained by 
the reduction in triglyceride level alone as this would equate to an 8% reduction 
rather than the 25% risk reduction that was observed. While a reduction in CRP as a 
marker of systemic inflammation was also reduced compared with baseline, it is 
estimated that this would only equate to an additional 5% benefit in CV risk 
reduction.  
A potential confounding factor is the choice of placebo, as mineral oil may 
promote the development of atherosclerosis or inflammation and is known to reduce 
the enteral absorption of other medications prescribed to mediate cardiovascular risk 
so theoretically this could have increased cardiovascular events in the control group. 
Similar trials in fish oil derivatives have also faced challenges in placebo selection 
due to the characteristic texture and aroma of the active drugs. 
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Other therapies which reduce triglyerides such as fibrates or niacin have 
conflicting evidence for overall cardiovascular benefit and utilisation is limited by 
significant side effect profiles and drug-interactions. The limited interactions and 
side-effect profile of icosapent ethyl make it an attractive option in the target patient 
population who are commonly on multiple additional medications. The results of 
further cardiovascular outcomes trials with n-3 fatty acids and fish oils are awaited 
with interest. 
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Key Points 
1. The n-3 fatty acid icosapent ethyl significantly reduced cardiovascular events 
when prescribed to people with diabetes or existing cardiovascular disease who 
were on statins and had raised triglycerides 
2. Compared with other triglyceride-lowering therapy like niacin or fibrates icosapent 
ethyl has been proven to reduced cardiovascular events, has fewer interactions 
and less side-effects 
3. The mechanism of benefit remains unclear and further evaluation and 
cardiovascular outcomes trials with n-3 fatty acids and fish oils are needed  
 
Legend to figure. 
Possible mechanisms of cardiovascular benefit of icosapent ethyl. 
